Leaving BNY Website

 

You are leaving the BNY Mellon's Depositary Receipts' Website.
Linked sites are not under the control of The Bank of New York Mellon Corporation or any of its subsidiaries or affiliates (together, the "Company") and the Company is not responsible for the content of any linked site or any link contained in a linked site. If you choose to link to a website not controlled by the Company, you do so entirely at your own risk and the Company makes no warranties, either express or implied, concerning the content of such site, including the accuracy, completeness, reliability or suitability thereof for any particular purpose, nor does the Company warrant that such site or content is free from any claims of copyright, trademark or other infringement of the rights of third parties or that such site or content is devoid of viruses or other contamination. The Company does not guarantee the authenticity of documents on the Internet. Links to other sites do not imply any endorsement of or responsibility for the opinions, ideas, products, information or services offered at such sites, or any representation regarding the content at such sites. The Company reserves the right to terminate any link at any time.

Do you wish to continue to the linked site on these terms?

Stay On Page
Leave Page

© 2025 The Bank of New York Mellon Corporation

Depositary Receipt business and services are conducted through The Bank of New York Mellon.

BNY - DR Legal Disclaimer
  

To learn more about DRs, please contact DRBrokerSolutions@bny.com.

 

The information and data provided herein are provided for general informational purposes only.  BNY does not warrant or guarantee the accuracy, timeliness or completeness of any such information or data.  BNY does not undertake any obligation to update or amend any information or data, and may change, update or amend any information or data at any time without prior notice.

 

BNY provides no advice, recommendation or endorsement with respect to any company or securities.  No information or data is intended to provide legal, tax, accounting, investment, financial, trading or other advice on any matter, and is not to be used as such.  We expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon any information or data, including market value loss on the sale or purchase of securities or other instruments or obligations.

 

Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.

 

BNY collects fees from DR holders pursuant to the terms and conditions of the DRs and any deposit agreement under which they are issued.  From time to time, BNY may make payments to an issuer to reimburse and/or share revenue from the fees collected from DR holders, or waive fees and expenses to an issuer for services provided, generally related to costs and expenses arising out of establishment and maintenance of the DR program.  BNY may pay a rebate to brokers in connection with unsponsored DR issuances; brokers may or may not disclose or pass back some or all of such rebate to the DR investor.  BNY may also use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions.

 

BNY may execute DR foreign currency transactions itself or through its affiliates, or the Custodian or the underlying Company may execute foreign currency transactions and pay US dollars to BNY.  In those instances where it executes DR foreign currency transactions itself or through its affiliates, BNY acts as principal counterparty and not as agent, advisor, broker or fiduciary.  In such cases, BNY  has no obligation to obtain the most favorable exchange rate, makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate. BNY earns and retains revenue on its executed foreign currency transactions based on, among other things, the difference between the rate it assigns to the transaction and the rate that it pays and receives for purchases and sales of currencies when buying or selling foreign currency for its own account.  The methodology used by BNY to determine DR conversion rates is available to registered Owners upon request or can be accessed here.  In those instances where BNY's Custodian executes DR foreign currency transactions, the Custodian has no obligation to obtain the most favorable exchange rate or that the method by which the rate will be determined will be the most favorable rate, and BNY makes no representation that the rate is a favorable rate and will not be liable for any direct or indirect losses associated with the rate.  In certain instances, BNY may receive dividends and other distributions from an issuer of securities underlying DRs in U.S. dollars rather than in a foreign currency.  In such cases, BNY will not engage in or be responsible for any foreign currency transactions and it makes no representation that the rate obtained by an issuer is a favorable rate and it will not be liable for any direct or indirect losses associated with the rate.

 

BNY is a global investments company dedicated to helping its clients manage and service their financial assets throughout the investment lifecycle.  BNY is the corporate brand of The Bank of New York Mellon Corporation (NYSE: BNY).

 

BNY's name, brand and/or trademarks may not be used, copied or reproduced without the prior express written consent of BNY.

 

DEPOSITARY RECEIPTS ARE NOT INSURED BY THE FDIC OR ANY OTHER GOVERNMENT AGENCY, ARE NOT DEPOSITS OR OTHER OBLIGATIONS OF, AND ARE NOT GUARANTEED BY, BNY AND ARE SUBJECT TO INVESTMENT RISKS INCLUDING POSSIBLE LOSS OF PRINCIPAL AMOUNT INVESTED.

 

Please also see "Terms of Use."

ACCEPT

Please enable cookies in your browser if you wish to proceed.

Regulation S Disclaimer

 

Access To This Company Profile Is Restricted To Non-U.S. Persons Outside The United States Within The Meaning Of Regulation S Under The U.S. Securities Act Of 1933, As Amended (The "Securities Act").1

 

This company profile does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction or under any circumstances in which such offer or solicitation is unlawful.

 

Each person accessing this company profile, by so doing, will be deemed to have acknowledged that: (1) It is not a U.S. person (within the meaning of Regulation S under the Securities Act) and is located outside the U.S. (within the meaning of Regulation S under the Securities Act); and (2) Any securities described herein (A) have not been and will not be registered under the Securities Act or with any securities regulatory authority of any state or other jurisdiction and (B) may not be offered, sold, pledged or otherwise transferred except to persons outside the U.S. in accordance with Regulation S under the Securities Act pursuant to the terms of such securities.

 

If you agree with and accept the foregoing and the Terms of use governing this site, please select "Accept" below. Otherwise, press "Decline" to return to the previous page.

 

1 As defined in the Securities Act, the term "U.S Person" means: (1) any natural person resident in the United States; (2) any partnership or corporation organized or incorporated under the laws of the United States; (3) any estate of which any executor or administrator is a U.S. person; (4) any trust of which any trustee is a U.S. person; (5) any agency or branch of a foreign entity located in the United States; (6) any non-discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary for the benefit or account of a U.S. person; (7) any discretionary account or similar account (other than an estate or trust) held by a dealer or other fiduciary organized, incorporated, or (if an individual) resident in the United States; and (8) any partnership or corporation if: (A) organized or incorporated under the laws of any foreign jurisdiction; and (B) formed by a U.S. person principally for the purpose of investing in securities not registered under the Securities Act, unless it is organized or incorporated, and owned, by accredited investors (as defined in Rule 501(a)) who are not natural persons, estates or trusts.

I Accept Decline

© 2024 The Bank of New York Mellon Corporation
Depositary Receipt business and services are conducted through The Bank of New York Mellon.

Back to Daily DR Market Summary

StreetAccount Summary - Europe Pre-Open: Futures FTSE +0.63%, DAX +0.62%, CAC40 +0.15%

Sep 30 ,2026

  • Synopsis

    • European equity markets are set for a positive open amidst mixed Asian equities Wednesday. Japan and Taiwan leading while South Korea erased opening gains. Greater China benchmarks little changed. S&P 500 futures higher afterhours. Bonds firming with Treasury yields down 1-2 bp at the long end. Japan 2Y yield holding declines after auction drew firmer demand than prior month's sale. Aussie curve bull steepening following soft CPI.

    • Rates stabilizing after Treasury 30Y yield touched highest in 24 years. Some reprieve from pullback in oil, and NY Fed's Williams downplaying urgency for near-term hike. Hawkish trend in monetary policy expectations, inflation pressures stemming in large part from higher oil prices and broadening Middle East conflict, AI investment boom, resilient US economic growth, and fiscal concerns remain the more widely cited drivers of the yield backup.

    • UK auto output rebounded in August. Dovish MPC member Taylor said he did not see a compelling case for a rate hike after hawkish-leaning comments from senior officials late last week. Press digests PM Burnham's speech from Tuesday, which include nationalization of utilities, changes to the state pension guarantee, electoral reform and closer ties with Europe.

    • Informal meeting of EU health ministers (through Thu). Chancellor Merz will deliver a keynote address at the annual meeting of the "Made for Germany" initiative, and at the conclusion of the event will hold a joint press statement with the CEO's of Siemens (SIE.GR) and Deutsche Bank (DBK.GR). EU's Šefčovič participates in the G20 Trade Ministerial (through Thu).

    • In central banks, ECB's Elderson panellist at 4:20CET at 24th International Conf of Banking Supervisors. Riksbank's Jansson gives a speech at 8:30BST about the economic situation and the latest interest rate decision at a breakfast seminar arranged by Nordea. ISDA Derivatives Trading and Treasury Forum sees BOE's Benjamin speaking at 11:25BST and Evans panellist at 14:50. LSE's CFM-RCM Lecture Series speaker at 18:00BST is the Honorary Governor of the Bank of France Villeroy. Riksbank releases minutes of last MPC meeting at 9:30CET. BOE releases minutes of last FPC meeting and SNB Quaretrly Bulletin is released at 15:00CET. Among the central bankers, politicians and company execs speaking at 8th Annual EC-EIB-ESM Capital Markets Seminar: Financing Europe, is ECB's Schnabel at 17:45CET.

    • A busy macro front sees Germany Sep unemployment rate, preliminary CPI, Aug retail sales, France Aug consumer goods spending, PPI, Sep preliminary CPI, Italy Sep business/consumer confidence, preliminary CPI, UK Q2 final GDP, Sep house price index - Nationwide, Switzerland Sep economic sentiment index, Netherlands Aug PPI, Sweden Aug retail sales, Denmark Q2 final GDP, Aug unemployment rate, Greece Jul retail sales, Aug unemployment rate, PPI, Portugal Sep preliminary CPI, Aug unemployment rate, retail sales, Ireland Sep unemployment rate, Austria Aug PPI

    • A slow earnings calendar sees Avantium (AVTX.NA), Santhera Pharmaceuticals Holding (SANN.SW), SkiStar (SKIS.B.SS) and GenSight Biologics (SIGHT.FP) out with reports.

  • Macro

    • Move to rejoin EU among options for UK, says Burnham - BBC

    • UK business morale hits 17-month low, Lloyds says - Reuters

    • Vanguard warns France is 'degrading credit' as borrowing costs surge - FT

  • Top company news

    • Earnings/updates

      • Benelux

        • AVTX.NA (Avantium) -- reports H1 EPS (€0.88) vs year-ago (€1.08)

      • DACHs

        • SANN.SW (Santhera Pharmaceuticals Holding) -- reports H1 EPS (CHF1.50) vs year-ago (CHF3.04)

      • Nordics

        • SKIS.B.SS (SkiStar) -- reports Q4 EPS (SEK2.87) vs FactSet (SEK3.11) [4 est, (SEK3.20)-(3.00)]

      • Southern Europe

        • SIGHT.FP (GenSight Biologics) -- reports H1 net income €10.3M vs year-ago €7.0M

        • ALTHX.FP (THX Pharma) -- reports H1 net income (€0.1M) vs year-ago (€1.1M)

        • JUVE.IM (Juventus Football Club) -- reports FY net income (€66.0M) vs year-ago (€58.1M)

    • M&A

      • TRIFOR.DC (Trifork Group) -- convenes EGM to approve special dividend and increase capital band

      • ARCAD.NA (Arcadis) -- to sell majority of its Greater China business to management team; terms undisclosed

      • XERS (Xeris Biopharma Holdings) -- H. Lundbeck (HLUN.B.DC) has expressed interest in buying Xeris Biopharma Holdings -- Bloomberg

      • TRN.IM (TERNA Rete Elettrica Nazionale) -- completes the sale of its electricity transmission assets in Peru

      • AKER.NO (Aker ASA) -- announces conditions for completion of merger with Aker BioMarine satisfied; merger to take place on 1-Oct-26 after the close

      • LOGI.B.SS (Logistea) -- acquires ~SEK1.01M portfolio in Denmark

      • HWG.LN (Harworth Group) -- Goodweather Holdings offer for Harworth Group declared unconditional

      • ANIC.LN (Agronomics) -- Agronomics provides update on Liberation Bioindustries

    • Healthcare

      • CANTA.SS (Cantargia) -- announced the presentation of a poster on nadunolimab in combination with RAS inhibition in pancreatic ductal adenocarcinoma (PDAC) at the AACR Conference on Pancreatic Cancer

      • ROP.SW (Roche Holding) -- Genentech's Fenebrutinib Is the First BTK Inhibitor to Receive U.S. FDA Filing Acceptance in Both Relapsing and Primary Progressive Multiple Sclerosis

      • ROP.SW (Roche Holding) -- Roche launches newborn screening test for three severe genetic conditions

      • UCB.BB (UCB) -- presents new data at EADV 2026 supporting earlier use of BIMZELX for treating hidradenitis suppurativa

      • GMAB.DC (Genmab) -- NICE recommends Genmab's Darzalex with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when a stem cell transplant is suitable

      • DBV.FP (DBV Technologies) -- submits BLA to FDA for VIASKIN Peanut Patch in children aged 4-7 Years

      • FRE.GR (Fresenius) -- FDA publishes warning letter sent to Fresenius Kabi for CGMP violations observed at Illinois facility

      • ZEAL.DC (Zealand Pharma) -- to present additional data from Phase 2 ZUPREME-1 trial for petrelintide at EASD

      • GALD.SW (Galderma Group) -- Galderma's New Data Show Sustained Improvements with Nemluvio (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis

      • EKTA.B.SS (Elekta) -- announces new phase 2 data on the Leksell Gamma Knife at ASTRO

      • ALM.SM (Almirall) -- to show new data for its biologic treatments, lebrikizumab in AD and tildrakizumab in PsO at EADV 2026

      • RENX.LN (Renalytix) -- Transcript Intelligence: Renalytix Investor Meeting

    • Other

      • 1AST.GR (ETV Montana Tech Holding) -- successfully completes placement of 500,000 shares in ASTA Energy Solutions AG at €60.00 per share

      • NDX1.GR (Nordex Group) -- secures 175 MW of new orders in France, Portugal and Spain

      • MAIRE.IM (MAIRE) -- awarded licensing, process design package and proprietary equipment supply in China based on its NX STAMI urea technology

      • BA.LN (BAE Systems) -- awarded $137.7M US Navy contract

      • LR.FP (Legrand) -- Transcript Intelligence: Legrand Capital Markets Day

      • IDR.SM (Indra Sistemas) -- announces management changes

      • NKT.DC (NKT A/S) -- Transcript Intelligence: NKT A/S Investor Day

      • KOG.NO (Kongsberg Gruppen) --

        • announces NOK 10B contract for NASAMS air defense system

        • announces NOK 1.5B contract with the Netherlands

      • Corby Spirit & Wine announces extension of Hiram Walker agreements

      • UK August vehicle manufacturing +5.7% y/y to 40,872 units - SMMT

  • Key rating changes

    • Upgrades

      • NKT.DC (NKT) -- to hold from reduce at Kepler Cheuvreux

      • BAER.SW (Julius Baer Group) -- equal-weight from underweight at Morgan Stanley

      • NSI.NA (NSI) -- neutral from underperform at Oddo

      • Macquarie upgrades GGP.AU, GGP.LN, WAF.AU; downgrades DPM.AU, DPM.CN (pre-Australia open)

      • Macquarie upgrades RIO.AU, RIO.LN; downgrades AMI.AU

      • Oddo upgrades FORTUM.FH, RED.SM, VER.AV; downgrades ENG.SM

      • Pareto upgrades DIS.IM, TRMD.A.DC

      • HAFNI.NO (Hafnia) -- to buy from hold at Pareto

      • KOG.NO (Kongsberg Gruppen) -- to buy from hold at DNB Carnegie

    • Downgrades

      • LISN.SW (Chocoladefabriken Lindt & Spruengli) -- underperform from neutral at Oddo

      • CBK.GR (Commerzbank) -- to hold from buy at Deutsche Bank

      • G.IM (Assicurazioni Generali) -- to hold from buy at Jefferies

    • Initiations

      • DOCM.SW (DocMorris) -- overweight at Cantor Fitzgerald

      • SINCH.SS (Sinch) -- sell at Pareto

      • ZEG.LN (Zegona Communications) -- buy at Goldman Sachs

  • Data

    • Nikkei +2.12% to 66870.76

    • Hang Seng +0.04% to 24534.40

    • Shanghai Composite +0.41% to 3846.12

    • S&P futures +13.3 vs prior close of 7732.0

    • €-$ +0.0000 or +0.00% to 1.1342

    • $-¥ (0.38) or (0.24%) to 156.91

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE

    • BNY.com Terms of Use Privacy Cookie Notice Manage Cookies Disclaimer CUSIP Disclaimer

    • ©  2025 The Bank of New York Corporation. Depositary Receipt business and services are conducted through The Bank of New York.